Article Data

  • Views 449
  • Dowloads 122

Reviews

Open Access Special Issue

Circulating tumor cells in metastatic breast cancer: ready for clinical practice?

  • Laura Brus1
  • Donata Grimm-Glang2,3
  • Natalia Krawczyk4
  • Tanja Fehm4
  • Achim Rody2
  • Peter Paluchowski1
  • Maggie Banys-Paluchowski2,*,

1Department of Gynecology and Obstetrics, Regio Klinikum Pinneberg, 25421 Pinneberg, Germany

2Department of Gynecology and Obstetrics, University Medical Center Schleswig-Holstein, Campus-Lübeck, 23538 Lübeck, Germany

3Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany

4Department of Gynecology and Obstetrics, Heinrich-Heine-University Düsseldorf, 40225 Düsseldorf, Germany

DOI: 10.22514/ejgo.2022.007 Vol.43,Issue 3,June 2022 pp.4-8

Submitted: 13 December 2021 Accepted: 10 May 2022

Published: 15 June 2022

(This article belongs to the Special Issue Breast Cancer)

*Corresponding Author(s): Maggie Banys-Paluchowski E-mail: m.banys@outlook.com

Abstract

Circulating tumor cells (CTCs) have emerged as a promising new biomarker in breast cancer and various settings in which liquid biopsy may improve diagnostics are currently under discussion. In patients with metastatic disease, high CTC counts have been shown to predict poor prognosis with level I evidence. Persistence of elevated CTC numbers after begin of systemic treatment is associated with higher risk of progression. This review discusses current evidence on the clinical use of CTC diagnostics in metastatic breast cancer.


Keywords

circulating tumor cells; CTCs; liquid biopsy; breast cancer; metastatic breast cancer; therapy interventions


Cite and Share

Laura Brus,Donata Grimm-Glang,Natalia Krawczyk,Tanja Fehm,Achim Rody,Peter Paluchowski,Maggie Banys-Paluchowski. Circulating tumor cells in metastatic breast cancer: ready for clinical practice?. European Journal of Gynaecological Oncology. 2022. 43(3);4-8.

References

[1] Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, et al. Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Annals of Oncology. 2015; 26: 1533–1546.

[2] Chen K, Lu P, Beeraka NM, Sukocheva OA, Madhunapantula SV, Liu J, et al. Mitochondrial mutations and mitoepigenetics: Focus on regulation of oxidative stress-induced responses in breast cancers. Seminars in Cancer Biology. 2020. (in press)

[3] Janni WJ, Rack B, Terstappen LWMM, Pierga J, Taran F, Fehm T, et al. Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer. Clinical Cancer Research. 2016; 22: 2583–2593.

[4] Martín M, Custodio S, Casas MM, García-Sáenz J, Torre J, Bellón-Cano J, et al. Circulating Tumor Cells Following first Chemotherapy Cycle: an Early and Strong Predictor of Outcome in Patients with Metastatic Breast Cancer. The Oncologist. 2013; 18: 917–923.

[5] Rack B, Schindlbeck C, Jückstock J, Andergassen U, Hepp P, Zwingers T, et al. Circulating Tumor Cells Predict Survival in Early Average-to-High Risk Breast Cancer Patients. Journal of the National Cancer Institute. 2014; 106: doi/10.1093/jnci/dju273.

[6] Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC, et al. A Pooled Analysis of Bone Marrow Micrometastasis in Breast Cancer. New England Journal of Medicine. 2005; 353: 793–802.

[7] Pantel K, Brakenhoff RH, Brandt B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nature Reviews Cancer. 2008; 8: 329–340.

[8] Cristofanilli M, Pierga J, Reuben J, Rademaker A, Davis AA, Peeters DJ, et al. The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper. Critical Reviews in Oncology/Hematology. 2019; 134: 39–45.

[9] Bidard F, Peeters DJ, Fehm T, Nolé F, Gisbert-Criado R, Mavroudis D, et al. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. The Lancet Oncology. 2014; 15: 406–414.

[10] Banys-Paluchowski M, Krawczyk N, Fehm T. Potential Role of Circulating Tumor Cell Detection and Monitoring in Breast Cancer: A Review of Current Evidence. Frontiers in Oncology. 2016; 6: 255.

[11] Banys-Paluchowski M, Fehm T, Janni W, Solomayer E, Hartkopf A. Circulating and Disseminated Tumor Cells in Breast Carcinoma. Geburtshilfe Und Frauenheilkunde. 2019; 79: 1320–1327.

[12] Müller V, Banys-Paluchowski M, Friedl TWP, Fasching PA, Schneeweiss A, Hartkopf A, et al. Prognostic relevance of the her2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program. ESMO Open. 2021; 6: 100299.

[13] Bidard F, Michiels S, Riethdorf S, Mueller V, Esserman LJ, Lucci A, et al. Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: a Meta-analysis. Journal of the National Cancer Institute. 2018; 110: 560–567.

[14] Smerage JB, Barlow WE, Hortobagyi GN, Winer EP, Leyland-Jones B, Srkalovic G, et al. Circulating Tumor Cells and Response to Chemotherapy in Metastatic Breast Cancer: SWOG S0500. Journal of Clinical Oncology. 2014; 32: 3483–3489.

[15] Janni WJ, Yab TC, Hayes DF, Cristofanilli M, Bidard F, Ignatiadis M, et al. Abstract GS4-08: Clinical utility of repeated circulating tumor cell (CTC) enumeration as early treatment monitoring tool in metastatic breast cancer (MBC) - a global pooled analysis with individual patient data. Cancer Research. 2021; 81: GS4-08.

[16] Cabel L, Berger F, Cottu P, Loirat D, Rampanou A, Brain E, et al. Clinical utility of circulating tumour cell-based monitoring of late-line chemotherapy for metastatic breast cancer: the randomised CirCe01 trial. British Journal of Cancer. 2021; 124: 1207–1213.

[17] Bidard F, Jacot W, Kiavue N, Dureau S, Kadi A, Brain E, et al. Efficacy of Circulating Tumor Cell Count–Driven vs Clinician-Driven first-line Therapy Choice in Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer. JAMA Oncology. 2021; 7: 34.

[18] Fehm T, Müller V, Banys-Paluchowski M, fasching PA, Friedl TWP, Hartkopf A, et al. Abstract PD3-12: Efficacy of the tyrosine kinase inhibitor lapatinib in the treatment of patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells -results from the randomized phase III DETECT III trial. Cancer Research. 2021; 81: PD3-12.

[19] Bidard F, Jacot W, Dureau S, Brain E, Bachelot T, Bourgeois H, et al. Abstract GS3-07: Clinical utility of circulating tumor cell count as a tool to chose between first line hormone therapy and chemotherapy for ER+ her2- metastatic breast cancer: Results of the phase III STIC CTC trial. Cancer Research. 2019; 79: GS3-07.

[20] Fehm T, Müller V, Aktas B, Janni W, Schneeweiss A, Stickeler E, et al. Her2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. Breast Cancer Research and Treatment. 2010; 124: 403–412.

[21] Banys-Paluchowski M, Hartkopf A, Meier-Stiegen F, Janni W, Solo-mayer E, Fehm T. Circulating and Disseminated Tumour Cells in Breast Carcinoma. Geburtshilfe Und Frauenheilkunde. 2019; 79: 177–183.


Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top